Skip to main content
    S

    Seres Therapeutics Inc (MCRB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.41
    +0.01 (+0.71%)

    Market Cap: $14.27M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Seres Therapeutics Inc (MCRB) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Seres Therapeutics reported revenue of $789.00K for the fiscal year ended Dec 31, 2025. That year, net income was $5.70M with a net margin of 721.9%, operating cash flow was $1.12M and free cash flow was $865.00K. The quarter ended Sep 30, 2026 had revenue of $593.00K and net income of -$16.29M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $21.77M, a compound annual decline of 30.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$789.00KN/A100.0%-11910.1%721.9%
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$144.93M+336.3%100.0%-44.5%-45.2%
    Dec 2020$33.22M-3.7%100.0%-265.3%-268.3%
    Dec 2019$34.51M+22.1%100.0%-208.3%-203.7%
    Dec 2018$28.27M-11.9%100.0%-354.8%-350.0%
    Dec 2017$32.10M+47.5%100.0%-284.7%-278.4%
    Dec 2016$21.77MN/A100.0%-426.5%-420.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 4091.2% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$789.00K$0$0$0$144.93M$33.22M$34.51M$28.27M$32.10M$21.77M
    Gross profit$789.00K$0$0$0$144.93M$33.22M$34.51M$28.27M$32.10M$21.77M
    Research and development$49.06M$64.60M$117.60M$109.65M$141.89M$90.57M$80.14M$95.95M$89.45M$81.99M
    Operating income-$93.97M-$121.31M-$195.10M-$179.91M-$64.49M-$88.13M-$71.88M-$100.28M-$91.39M-$92.84M
    Net income$5.70M$136.00K-$113.72M-$250.16M-$65.58M-$89.13M-$70.28M-$98.94M-$89.38M-$91.58M
    EBITDA$7.60MN/A-$187.82M-$172.60M-$56.57M-$79.57M-$63.10M-$92.47M-$83.50M-$89.02M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$593.00K$736.00K$358.00K$438.00K$351.00K$0$0$5.96M$0$0$0-$125.95M
    Gross profit$593.00K$736.00K$358.00K$438.00K$351.00K$0$0-$5.13M$0$0$0-$125.95M
    Operating income-$16.15M-$21.27M-$20.91M-$19.38M-$22.48M-$24.88M-$27.24M-$28.84M-$29.17M-$28.87M-$34.44M-$129.47M
    Net income-$16.29M$4.58M-$19.91M-$15.34M$8.20M-$19.86M$32.68M-$15.64M$88.78M-$32.87M-$40.13M-$41.25M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $10.39M by $35.38M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$138.19M$139.81M$358.60M$348.78M$354.86M$342.94M$132.44M$120.47M$189.52M$272.65M
    Current assets$49.38M$38.67M$175.41M$194.76M$303.63M$268.78M$100.19M$92.67M$155.08M$198.37M
    Cash and equivalents$45.77M$30.79M$127.97M$163.03M$180.00M$116.05M$65.13M$85.82M$36.09M$54.54M
    Total liabilities$93.97M$126.03M$403.46M$338.00M$223.35M$168.19M$180.76M$168.52M$128.82M$140.01M
    Short-term debt$10.39M$8.67M$5.59M$456.00K$0$454.00K$0$12.07M$9.22M$7.50M
    Long-term debtN/AN/A$101.54M$50.59M$24.64M$24.64M$24.65MN/A$0$0
    Shareholder equity$44.22M$13.78M-$44.86M$10.78M$131.51M$174.75M-$48.32M-$48.05M$60.70M$132.63M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$65.89M$101.59M$117.62M$138.19M$143.47M$143.80M$164.18M$139.81M$178.74M$321.73M$341.26M$358.60M
    Total liabilities$44.53M$67.05M$91.12M$93.97M$99.78M$110.85M$113.72M$126.03M$154.82M$408.81M$401.00M$403.46M
    Cash and equivalents$17.53M$15.59M$29.83M$45.77M$47.64M$45.38M$58.85M$30.79M$66.82M$71.23M$111.18M$127.97M
    Shareholder equity$21.36M$34.53M$26.50M$44.22M$43.70M$32.95M$50.47M$13.78M$23.92M-$87.07M-$59.74M-$44.86M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 77.2% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$1.12M-$148.61M-$117.35M-$228.82M$6.69M-$93.61M-$76.52M-$62.85M-$75.52M$43.92M
    Capital expenditures$252.00K$380.00K$7.97M$9.82M$9.57M$591.00K$1.00M$1.94M$4.68M$21.49M
    Free cash flow$865.00K-$148.99M-$125.33M-$238.64M-$2.88M-$94.20M-$77.52M-$64.79M-$80.20M$22.43M
    Investing cash flow-$42.00K$142.29M$10.58M$82.43M$64.09M-$158.89M-$30.52M$112.32M$55.70M-$65.59M
    Financing cash flow$13.90M-$90.37M$71.70M$129.60M$1.18M$303.42M$86.23M$268.00K$83.00K$2.14M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$10.48M-$22.39M-$16.36M-$14.71M$2.21M-$13.29M$26.91M-$38.88M-$34.68M-$39.81M-$35.24M-$47.50M
    Capital expendituresN/AN/A$0$29.00K$8.00K$181.00K$34.00K$90.00K$129.00K$99.00K$62.00K$877.00K
    Free cash flowN/AN/A-$16.36M-$14.74M$2.20M-$13.47M$26.88M-$38.97M-$34.81M-$39.91M-$35.30M-$48.38M
    Last 12 quarters

    Frequently Asked Questions About MCRB

    What is Seres Therapeutics' annual revenue?

    Seres Therapeutics reported revenue of $789.00K for the fiscal year ended Dec 31, 2025.

    Is Seres Therapeutics profitable?

    Yes. Seres Therapeutics reported net income of $5.70M for the fiscal year ended Dec 31, 2025, with a net margin of 721.9%.

    How much free cash flow does MCRB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $1.12M minus capital expenditures of $252.00K produced free cash flow of $865.00K.

    How much debt does Seres Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $10.39M and cash and equivalents of $45.77M.

    What is MCRB's profit margin?

    For the fiscal year ended Dec 31, 2025, Seres Therapeutics reported gross margin of 100.0%, operating margin of -11910.1% and net margin of 721.9%.